Lisuride

Lisuride

Clinical data
Routes of administration	Oral, subcutaneous, transdermal
ATC code	G02CB02 (WHO) N02CA07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	10-20% for lisuride hydrogenmaleate
Protein binding	about 15%
Metabolism	Hepatic
Elimination half-life	2 hours
Excretion	renal and biliary in equal amounts
Identifiers
CAS Number	18016-80-3
PubChem CID	28864
DrugBank	APRD00636
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H26N4O
Molar mass	338.447 g/mol

Lisuride (brand name in Germany Dopergin) is an anti-Parkinson's drug of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogenmaleate salt.

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. Lisuride is not currently available in the US.

Mode of action

Lisuride is a dopamine agonist.

Commercial names

Name	Country of Use
Arolac	France
Cuvalit	Germany
Dipergon	Greece
Dopergin(e)	Germany, Spain, France, China
Dopergine	Belgium
Lysenyl Forte	Czech Republic, Slovakia
Prolacam	Australia
Revanil	UK

History

Synthesis of lisuride was first described in 1960.

Indications

• Parkinson's Disease

See also

• Dopamine receptor